Vincerx Pharma, Inc., formerly Vincera Pharma, Inc., is a clinical-stage life sciences company. The Company focuses on the development and oncology knowledge to advance new therapies for the treatment of cancer. The Company’s small molecule drug program includes VIP152, a clinical-stage positive transcription elongation factor beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. Its antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924...